Researchers have recently shed light on the impact of high-efficacy therapies on specific brain structures in chronic neuroinflammatory conditions. In a new clinical study, experts evaluated the effects of ocrelizumab cortical pathology management in patients with relapsing-remitting multiple sclerosis (RRMS). Cortical lesions (CLs) are widely recognized as early markers of disease severity. However, longitudinal data regarding how modern treatments influence these specific lesions have remained limited until now. This research highlights the potential for B-cell therapies to stabilize the grey matter environment more effectively than previously understood.

Evaluating Ocrelizumab Cortical Pathology and Brain Metrics

The study followed 87 RRMS patients over a two-year period using high-resolution 3T MRI imaging. To ensure precision, researchers employed Artificial Intelligence-Driven Imaging Reconstruction (AIDIR) sequences for manual lesion segmentation. At the baseline assessment, nearly 76% of patients exhibited at least one cortical lesion. Importantly, the results showed that higher lesion volumes correlated strongly with reduced total brain volume and lower cognitive performance scores. These findings confirm that cortical involvement serves as a critical indicator of early cognitive and structural decline.

The most striking result of the follow-up was the near-total suppression of new cortical damage. While approximately 16% of the cohort experienced new white matter lesion accrual, only one single patient developed a new cortical lesion. This remarkable outcome suggests that ocrelizumab effectively minimizes the accrual of grey matter damage even when some white matter activity persists. Furthermore, the evidence indicates that the drug may play a vital role in preventing lesion-driven cortical atrophy over the short term. Consequently, this treatment offers a promising pathway for preserving brain tissue integrity in young MS patients.

Clinical Implications for MS Management

These findings suggest that distinct biological mechanisms likely drive the development of cortical versus white matter lesions. Because ocrelizumab appears to stabilize cortical pathology so effectively, it offers a protective benefit for long-term cognitive and physical function. Clinicians should increasingly consider cortical monitoring as a key component of assessing treatment response. Additionally, the study supports the early use of high-efficacy infusions to prevent the cumulative burden of grey matter inflammation. Overall, the data reinforce ocrelizumab as a potent tool for achieving no evidence of disease activity (NEDA) in the cortex.

Frequently Asked Questions

What are cortical lesions in multiple sclerosis?

Cortical lesions are areas of inflammatory damage within the grey matter of the brain. Unlike traditional white matter lesions, they are often harder to detect on standard MRI but serve as major predictors of cognitive decline and physical disability in MS patients.

How does ocrelizumab benefit cortical health?

Ocrelizumab helps stabilize ocrelizumab cortical pathology by significantly preventing the formation of new lesions in the grey matter. Research indicates it may also slow down the neurodegenerative process and brain volume loss associated with these specific lesions.

Why is AIDIR imaging important in MS?

Artificial Intelligence-Driven Imaging Reconstruction (AIDIR) enhances the clarity of MRI scans. This technology allows radiologists to identify small cortical lesions that might be missed during routine clinical imaging, leading to more accurate disease monitoring.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Cavalli N et al. Short-term effects of ocrelizumab on cortical pathology in patients with multiple sclerosis. Neurotherapeutics. 2026 Jun 08. doi: undefined. PMID: 42258988.


2. Dwyer MG et al. New imaging confirms ocrelizumab's impact on lesion activity in multiple sclerosis. Healio. March 11, 2025.


3. Butzkueven H et al. CMSC 2026: Real-World Analysis Supports Ocrelizumab Use in Pediatric-Onset Multiple Sclerosis. NeurologyLive. May 29, 2026.